 | • レポートコード：MRC-IM30222 • 出版社/出版日：IMARC / 2022年11月 • レポート形態：英文、PDF、145ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥374,850 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥674,850 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| グローバル調査会社のIMARC社は、2021年に69億ドルであった世界の神経バイオマーカー市場規模が、2022年から2027年の間にCAGR 13.5％で成長し、2027年までに146億ドルに達すると予測しています。本調査レポートでは、神経バイオマーカーの世界市場について総合的に調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、種類別（ゲノムバイオマーカー、プロテオームバイオマーカー、メタボロームバイオマーカー、イメージングバイオマーカー、その他）分析、用途別（アルツハイマー病、パーキンソン病、多発性硬化症、自閉症スペクトラム障害、その他）分析、最終用途別（病院検査室、臨床診断センター、研究機関、その他）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目をまとめています。なお、本書に掲載されている企業情報には、Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm Inc. (Myriad Genetics Inc.), Proteome Sciences Plcなどが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の神経バイオマーカー市場規模：種類別 - ゲノムバイオマーカーの市場規模 - プロテオームバイオマーカーの市場規模 - メタボロームバイオマーカーの市場規模 - イメージングバイオマーカーの市場規模 - その他神経バイオマーカーの市場規模 ・世界の神経バイオマーカー市場規模：用途別 - アルツハイマー病における市場規模 - パーキンソン病における市場規模 - 多発性硬化症における市場規模 - 自閉症スペクトラム障害における市場規模 - その他用途における市場規模 ・世界の神経バイオマーカー市場規模：最終用途別 - 病院検査室における市場規模 - 臨床診断センターにおける市場規模 - 研究機関における市場規模 - その他最終用途における市場規模 ・世界の神経バイオマーカー市場規模：地域別 - 北米の神経バイオマーカー市場規模 - アジアの神経バイオマーカー市場規模 - 欧州の神経バイオマーカー市場規模 - 中南米の神経バイオマーカー市場規模 - 中東・アフリカの神経バイオマーカー市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global neurological biomarkers market size reached US$ 6.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 14.6 Billion by 2027, exhibiting a growth rate (CAGR) of 13.5% during 2022-2027.
Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments.
The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, application and end use.
Breakup by Type:
Genomic Biomarkers
Proteomic Biomarkers
Metabolomic Biomarkers
Imaging Biomarkers
Others
Breakup by Application:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
Breakup by End Use:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
How has the global neurological biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global neurological biomarkers market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global neurological biomarkers market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Neurological Biomarkers Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Genomic Biomarkers
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Proteomic Biomarkers
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Metabolomic Biomarkers
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Imaging Biomarkers
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Application
7.1 Alzheimer’s Disease
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Parkinson’s Disease
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Multiple Sclerosis
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Autism Spectrum Disorders
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by End Use
8.1 Hospital Laboratories
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Clinical Diagnostic Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Research Organizations
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Acumen Pharmaceuticals Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Athena Diagnostics (Quest Diagnostics)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Banyan Biomarkers Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Bio-Rad Laboratories Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Immunarray Pvt. Ltd.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Proteome Sciences Plc
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Thermo Fisher Scientific Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
Figure 2: Global: Neurological Biomarkers Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Neurological Biomarkers Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Neurological Biomarkers Market: Breakup by Type (in %), 2021
Figure 5: Global: Neurological Biomarkers Market: Breakup by Application (in %), 2021
Figure 6: Global: Neurological Biomarkers Market: Breakup by End Use (in %), 2021
Figure 7: Global: Neurological Biomarkers Market: Breakup by Region (in %), 2021
Figure 8: Global: Neurological Biomarkers (Genomic Biomarkers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Neurological Biomarkers (Genomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Neurological Biomarkers (Proteomic Biomarkers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Neurological Biomarkers (Proteomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Neurological Biomarkers (Imaging Biomarkers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Neurological Biomarkers (Imaging Biomarkers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Neurological Biomarkers (Alzheimer's Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Neurological Biomarkers (Alzheimer's Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Neurological Biomarkers (Parkinson's Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Neurological Biomarkers (Parkinson's Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Neurological Biomarkers (Multiple Sclerosis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Neurological Biomarkers (Multiple Sclerosis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Global: Neurological Biomarkers (Hospital Laboratories) Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Global: Neurological Biomarkers (Hospital Laboratories) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Global: Neurological Biomarkers (Research Organizations) Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Global: Neurological Biomarkers (Research Organizations) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: North America: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: North America: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: United States: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: United States: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Canada: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: Canada: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Asia-Pacific: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Asia-Pacific: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: China: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: China: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Japan: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Japan: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: India: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: India: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: South Korea: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: South Korea: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: Australia: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: Australia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Indonesia: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Indonesia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Europe: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Europe: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Germany: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Germany: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: France: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: France: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: United Kingdom: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: United Kingdom: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Italy: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Italy: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Spain: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Spain: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Russia: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Russia: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 74: Latin America: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 75: Latin America: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 76: Brazil: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 77: Brazil: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Mexico: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 79: Mexico: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 80: Others: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 81: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 82: Middle East and Africa: Neurological Biomarkers Market: Sales Value (in Million US$), 2016 & 2021
Figure 83: Middle East and Africa: Neurological Biomarkers Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Middle East and Africa: Neurological Biomarkers Market: Breakup by Country (in %), 2021
Figure 85: Global: Neurological Biomarkers Industry: SWOT Analysis
Figure 86: Global: Neurological Biomarkers Industry: Value Chain Analysis
Figure 87: Global: Neurological Biomarkers Industry: Porter's Five Forces Analysis